The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2015

Filed:

Nov. 06, 2009
Applicants:

Louis M. Pelus, Indianapolis, IN (US);

Jonathan Hoggatt, Cambridge, MA (US);

Pratibha Singh, Indianapolis, IN (US);

Inventors:

Louis M. Pelus, Indianapolis, IN (US);

Jonathan Hoggatt, Cambridge, MA (US);

Pratibha Singh, Indianapolis, IN (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); C12N 15/00 (2006.01); C12N 15/63 (2006.01); A61K 48/00 (2006.01); A61K 31/405 (2006.01); A61K 31/00 (2006.01); C12N 5/0789 (2010.01); A61K 31/395 (2006.01); A61K 31/5415 (2006.01); A61K 35/14 (2015.01); A61K 35/28 (2015.01); A61K 35/50 (2015.01); A61K 35/51 (2015.01); A61K 38/19 (2006.01); C12N 9/02 (2006.01); C12N 5/16 (2006.01); C12N 15/86 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
A61K 31/405 (2013.01); A61K 31/00 (2013.01); A61K 31/395 (2013.01); A61K 31/5415 (2013.01); A61K 35/14 (2013.01); A61K 35/28 (2013.01); A61K 35/50 (2013.01); A61K 35/51 (2013.01); A61K 38/193 (2013.01); C12N 5/0647 (2013.01); C12N 9/0083 (2013.01); A61K 2035/124 (2013.01); C12N 5/16 (2013.01); C12N 15/63 (2013.01); C12N 15/86 (2013.01); C12N 2501/02 (2013.01); C12Y 114/99001 (2013.01);
Abstract

This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGEbiosynthesis or PGEreceptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGEinclude non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGEor at least one of its derivatives such as 16,16-dimethyl prostaglandin E(dmPGE), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.


Find Patent Forward Citations

Loading…